mProX™ Human CEACAM5 Stable Cell Line

Everest-Dass, Arun. et al. "Spontaneous metastasis xenograft models link CD44 isoform 4 to angiogenesis, hypoxia, EMT and mitochondria-related pathways in colorectal cancer." Molecular oncology, 2023.
The survival of colorectal cancer (CRC) patients is limited due to hematogenous metastasis. In this study, the roles of CD44 isoforms in this process were investigated. It was found that isoforms 3 and 4 were predominantly expressed in CRC patients, with isoform 4 being associated with poor outcomes and correlated with epithelial-mesenchymal transition (EMT) and decreased oxidative phosphorylation. Knockdown of pan-CD44 led to impaired primary tumor formation and blocked distant metastasis in CRC xenografts, which mainly expressed CD44 isoforms 3 and 4. Hypoxic tumor regions showed increased levels of both isoforms, while lung metastases were generally negative for them. CD44 knockdown also led to increased tumor angiogenesis and changes in the expression of hypoxia-related genes and proteins. Mitochondrial genes and proteins were induced upon CD44 knockdown, with a corresponding increase in oxidative phosphorylation genes. Additionally, hypoxia-induced release of VEGF from tumor spheres was enhanced after CD44 knockdown. The genes affected by CD44 knockdown in xenografts were found to be concordant with those correlated with CD44 isoform 4 (but not isoform 3) in patients, further supporting the clinical relevance of this model and highlighting the metastasis-promoting role of CD44 isoform 4.
Everest-Dass, Arun. et al. "Spontaneous metastasis xenograft models link CD44 isoform 4 to angiogenesis, hypoxia, EMT and mitochondria-related pathways in colorectal cancer." Molecular oncology, 2023.
Pubmed: 37849446   DOI: 10.1002/1878-0261.13535

Cui, Ming. et al. "Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm." Signal transduction and targeted therapy, 2023.
Pancreatic cystic neoplasms (PCNs) are known to act as precursor lesions for pancreatic cancer and have shown a significant increase in prevalence. Detecting malignant PCNs early on is crucial for improving prognosis; however, the current diagnostic methods are inadequate in accurately identifying malignancy. A team of researchers utilized mass spectrometry (MS)-based glycosite- and glycoform-specific glycoproteomics, along with proteomics, to investigate potential cyst fluid biomarkers for PCN. The glycoproteomic and proteomic landscape of pancreatic cyst fluid samples from PCN patients was comprehensively analyzed, and its changes during the malignant transformation of PCN were studied. Following specific screening criteria for cyst fluid biomarkers, a group of promising glycoprotein biomarkers were identified. Through parallel reaction monitoring (PRM)-based targeted glycoproteomic analysis, the chosen glycoprotein biomarkers were validated in a second cohort, ultimately confirming their diagnostic potential for distinguishing malignant PCNs. These glycoprotein biomarkers displayed strong performance, with an area under the curve ranging from 0.771 to 0.948. In conclusion, the research team successfully utilized MS-based glycoproteomic analysis to identify novel cyst fluid glycoprotein biomarkers for PCN. These findings hold significant clinical implications, providing valuable insights for PCN diagnosis and treatment decision-making, and potentially identifying therapeutic targets for PCN treatment.
Cui, Ming. et al. "Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm." Signal transduction and targeted therapy, 2023.
Pubmed: 37848412   DOI: 10.1038/s41392-023-01645-8